ClinicalTrials.gg
CompletedNCT00902174IMPRESUpdated Feb 17, 2016Results posted

Imatinib (QTI571) in Pulmonary Arterial Hypertension

A Phase 3 interventional study of imatinib mesylate and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 95 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
2nd of 12
202 · median 27
Started
2009
the only one that year
Phase 3
5 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 2nd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension
  • Imatinib
  • 6MWD
  • Borg scale
  • Pulmonary hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  • Male or female patients ≥18 years of age with a current diagnosis of pulmonary arterial hypertension (PAH) according to the Dana Point 2008 Meeting: World Health Organization (WHO) Diagnostic Group I, idiopathic or heritable (familial or sporadic) PAH, PAH associated with collagen vascular disease including systemic sclerosis, rheumatoid arthritis, mixed connective tissue diseases, and overlap syndrome. PAH following one year repair of congenital heart defect [Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD) or Posterior Descending Artery (PDA)], or PAH associated with diet therapies or other drugs
  • A Pulmonary Vascular Resistance (PVR) ≥ 800 dynes.sec.cm-5 (as assessed by Right Heart Catheterization (RHC) at screening or in the 3 months preceding the screening visit) despite treatment with two or more specific PAH therapies, including Endothelin Receptor Antagonists (ERAs), phosphodiesterase 5 inhibitors (PDE5), or subcutaneous, inhaled, intravenous or oral prostacyclin analogues for ≥ 3 months. Background therapy doses were to be stable for ≥ 30 days except for warfarin and prostacyclin analogues ( ≥ 30 days but doses could vary even within the month before enrollment).
  • World Health Organization functional Class II-IV. For WHO Functional Class IV, one of the 2 or more specific PAH therapies were to be an inhaled, subcutaneous, intravenous or oral prostacyclin analogue, unless the subject showed intolerance of prostacyclin analogues.
  • 6MWD ≥ 150 meters and ≤ 450 meters at screening. Distances of two consecutive 6MWTs were to be within 15% of one another.

Key Exclusion criteria

  • With a pulmonary capillary wedge pressure > 15 mm Hg to rule out PAH secondary to left ventricular dysfunction.
  • With a diagnosis of pulmonary artery or vein stenosis
  • (LVEF) \< 45%
  • With Disseminated Intravascular Coagulation (DIC)
  • With evidence of major bleeding or intracranial hemorrhage
  • With a history of elevated intracranial pressure
  • With a history of latent bleeding risk such as diabetic retinopathy, gastrointestinal bleeding due to gastric or duodenal ulcers, or colitis ulcerosa
  • With a > 450 msec for males and > 470 msec for females at screening and baseline in the absence of right bundle branch block.
  • With a history of ventricular tachycardia, ventricular fibrillation or ventricular flutter
  • With a history of Torsades de Pointes
  • With a history of long QT syndrome
  • Having undergone atrial septostomy in the 3 months prior to the screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    imatinib mesylate

    Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.

    Drug: imatinib mesylate

  • Placebo comparator
    Placebo

    Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.

    Drug: Placebo

Interventions

  • Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.

  • DrugPlacebo

    Placebo to imatinib 100 mg film coated tablets

06

What researchers measure

Primary outcomes

  1. Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks

    This standardized walk course was 30 meters in length. During the walk the participant was connected to a portable pulse oximeter via a finger probe. Participants were instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. The total distance walked (in meters) was recorded. Results were compared between the 2 groups.

    Time frame: 24 weeks

Secondary outcomes

  1. Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases

    Clinical worsening per participant was measured by the onset of any adjudicated event (all cause mortality; overnight hospitalization for worsening of Pulmonary Arterial Hypertension (PAH); worsening of WHO functional class by one level; 15% decline in Six Minute Walk Distance (6MWD) measured on two consecutive occasions) at 24 weeks treatment, comparing imatinib to placebo groups. A cox regression analysis model was used.

    Time frame: 24 weeks

  2. Change From Baseline in Right Atrial Pressure

    Change from baseline in right atrial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The right atrial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher right atrial pressure number indicates worsening.

    Time frame: baseline and week 24

  3. Change From Baseline in Mean Pulmonary Arterial Pressure

    Change from baseline in mean pulmonary arterial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The mean pulmonary arterial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher mean pulmonary arterial pressure number indicates worsening.

    Time frame: baseline and week 24

  4. Change From Baseline in Mean Pulmonary Capillary Wedge Pressure

    Change from baseline in mean pulmonary capillary wedge pressure (mmHg)was measured via right heart catheterization according to the local hospital procedures. The right atrial mean pulmonary capillary wedge pressure was assessed when the participant was in a stable hemodynamic rest state.

    Time frame: baseline and week 24

  5. Change From Baseline in Systemic Vascular Resistance

    Change from baseline in systemic vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The systemic vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in mean systemic vascular resistance indicates improvement.

    Time frame: baseline and week 24

  6. Change From Baseline in Pulmonary Vascular Resistance

    Change from baseline in pulmonary vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The pulmonary vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in pulmonary vascular resistance indicates improvement.

    Time frame: baseline and week 24

  7. Change From Baseline in Pulmonary Resistance Index

    Change from baseline in pulmonary resistance index (dynes\*sec\*cm\^-5/m2) was measured via right heart catheterization according to the local hospital procedures. The pulmonary resistance index was assessed when the participant was in a stable hemodynamic rest state. A reduction from baseline in pulmonary resistance index indicates improvement.

    Time frame: baseline and week 24

  8. Change From Baseline in Cardiac Output

    Change from baseline in cardiac output (L/min) was measured via right heart catheterization according to the local hospital procedures. The cardiac output was assessed when the participant was in a stable hemodynamic rest state. An increase from baseline (higher number) in cardiac output indicates improvement.

    Time frame: 24 weeks

  9. Change From Baseline in Systolic Arterial Blood Pressure

    Change from baseline in systolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The systolic arterial blood was assessed when the participant was in a stable hemodynamic rest state.

    Time frame: baseline and week 24

  10. Change From Baseline in Diastolic Arterial Blood Pressure

    Change from baseline in diastolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The diastolic arterial blood pressure was assessed when the participant was in a stable hemodynamic rest state.

    Time frame: baseline and week 24

  11. Change From Baseline in Heart Rate

    Change from baseline in heart rate (bpm) was measured via right heart catheterization according to the local hospital procedures. The heart rate was assessed when the participant was in a stable hemodynamic rest state.

    Time frame: 24 weeks

  12. Change in Borg Dyspnea Score During 6-minute Walk Test

    Change in Borg scale was measured at different time points at week 24. The Borg Scale consists of scale range of 0 to 10. Participants pointed to indicate their level of dyspnea before and at the end of exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). A reduction in this score indicates an improvement.

    Time frame: week 24

  13. Covariance of End of Study CAMPHOR Score

    The CAMPHOR test consists of 65 items and 3 scales. Two scales measure Health Related Quality of Life. 1) Symptoms: consists of 25 items measuring loss or abnormality of psychological, physiological or anatomical structure or function; further sub-divided into 3 subscales (energy, breathlessness and mood), 2) Disability: consists of 15 items measuring any restriction or lack of ability to perform an activity. 3) Quality of Life (QOL): consists of 25 items defining how individuals perceived ability and capacity to satisfy their needs. The 25-item symptom and QOL scales score from 0-25 where a higher score indicates the presence of more symptoms and poor QOL, respectively. The 15-item functioning scale scores 0-30; a higher score indicates poor functioning.

    Time frame: Week 24

  14. Plasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant

    Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.

    Time frame: predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168

  15. Plasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant

    Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.

    Time frame: predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168

07

Results

Posted Jul 16, 2013

Participant flow

Overall, 326 participants were screened, 202 participants were randomized (103 to Imatinib and 99 to placebo). Out of 202 participants randomized 201 participants received study drug treatment (103 received imatinib mesylate, 98 received placebo). One participant was randomized to the placebo group but did not receive any study treatment.

Participant flow — Overall Study
MilestoneImatinib MesylatePlacebo
Started10399
Completed6981
Not completed3418
Withdrew: Adverse event277
Withdrew: Lack of efficacy15
Withdrew: Death22
Withdrew: Withdrawal by subject21
Withdrew: Abnormal labs11
Withdrew: Protocol violation11
Withdrew: Administration problem01

Outcome measures

PrimaryDifference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks

This standardized walk course was 30 meters in length. During the walk the participant was connected to a portable pulse oximeter via a finger probe. Participants were instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. The total distance walked (in meters) was recorded. Results were compared between the 2 groups.

Time frame:
24 weeks
Reported as:
Least squares mean · meters
Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks
metersImatinibPlacebo
Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks382.94 ± 9.790351.18 ± 9.834
SecondaryClinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases

Clinical worsening per participant was measured by the onset of any adjudicated event (all cause mortality; overnight hospitalization for worsening of Pulmonary Arterial Hypertension (PAH); worsening of WHO functional class by one level; 15% decline in Six Minute Walk Distance (6MWD) measured on two consecutive occasions) at 24 weeks treatment, comparing imatinib to placebo groups. A cox regression analysis model was used.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases
percentage of participantsImatinibPlacebo
Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases35.932.7
SecondaryChange From Baseline in Right Atrial Pressure

Change from baseline in right atrial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The right atrial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher right atrial pressure number indicates worsening.

Time frame:
baseline and week 24
Reported as:
Least squares mean · mm Hg
Change From Baseline in Right Atrial Pressure
mm HgImatinibPlacebo
Change From Baseline in Right Atrial Pressure-1.02 ± 0.8510.68 ± 0.855
SecondaryChange From Baseline in Mean Pulmonary Arterial Pressure

Change from baseline in mean pulmonary arterial pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The mean pulmonary arterial pressure was assessed when the participant was in a stable hemodynamic rest state. A higher mean pulmonary arterial pressure number indicates worsening.

Time frame:
baseline and week 24
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Pulmonary Arterial Pressure
mm HgImatinibPlacebo
Change From Baseline in Mean Pulmonary Arterial Pressure-3.54 ± 1.5851.63 ± 1.586
SecondaryChange From Baseline in Mean Pulmonary Capillary Wedge Pressure

Change from baseline in mean pulmonary capillary wedge pressure (mmHg)was measured via right heart catheterization according to the local hospital procedures. The right atrial mean pulmonary capillary wedge pressure was assessed when the participant was in a stable hemodynamic rest state.

Time frame:
baseline and week 24
Reported as:
Least squares mean · mm Hg
Change From Baseline in Mean Pulmonary Capillary Wedge Pressure
mm HgImatinibPlacebo
Change From Baseline in Mean Pulmonary Capillary Wedge Pressure0.92 ± 0.693-0.05 ± 0.701
SecondaryChange From Baseline in Systemic Vascular Resistance

Change from baseline in systemic vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The systemic vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in mean systemic vascular resistance indicates improvement.

Time frame:
baseline and week 24
Reported as:
Least squares mean · dynes*sec*cm^-5
Change From Baseline in Systemic Vascular Resistance
dynes*sec*cm^-5ImatinibPlacebo
Change From Baseline in Systemic Vascular Resistance-467.84 ± 78.577-88.10 ± 77.183
SecondaryChange From Baseline in Pulmonary Vascular Resistance

Change from baseline in pulmonary vascular resistance (dynes\*sec\*cm\^-5) was measured via right heart catheterization according to the local hospital procedures. The pulmonary vascular resistance was assessed when the participant was in a stable hemodynamic rest state. Reduction from baseline in pulmonary vascular resistance indicates improvement.

Time frame:
baseline and week 24
Reported as:
Least squares mean · dynes*sec*cm^-5
Change From Baseline in Pulmonary Vascular Resistance
dynes*sec*cm^-5ImatinibPlacebo
Change From Baseline in Pulmonary Vascular Resistance-366.47 ± 67.67312.12 ± 68.963
SecondaryChange From Baseline in Pulmonary Resistance Index

Change from baseline in pulmonary resistance index (dynes\*sec\*cm\^-5/m2) was measured via right heart catheterization according to the local hospital procedures. The pulmonary resistance index was assessed when the participant was in a stable hemodynamic rest state. A reduction from baseline in pulmonary resistance index indicates improvement.

Time frame:
baseline and week 24
Reported as:
Least squares mean · dynes*sec*cm^-5/m2
Change From Baseline in Pulmonary Resistance Index
dynes*sec*cm^-5/m2ImatinibPlacebo
Change From Baseline in Pulmonary Resistance Index-221.29 ± 47.35521.92 ± 48.247
SecondaryChange From Baseline in Cardiac Output

Change from baseline in cardiac output (L/min) was measured via right heart catheterization according to the local hospital procedures. The cardiac output was assessed when the participant was in a stable hemodynamic rest state. An increase from baseline (higher number) in cardiac output indicates improvement.

Time frame:
24 weeks
Reported as:
Least squares mean · Liters/minute
Change From Baseline in Cardiac Output
Liters/minuteImatinibPlacebo
Change From Baseline in Cardiac Output1.17 ± 0.1820.29 ± 0.186
SecondaryChange From Baseline in Systolic Arterial Blood Pressure

Change from baseline in systolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The systolic arterial blood was assessed when the participant was in a stable hemodynamic rest state.

Time frame:
baseline and week 24
Reported as:
Least squares mean · mm Hg
Change From Baseline in Systolic Arterial Blood Pressure
mm HgImatinibPlacebo
Change From Baseline in Systolic Arterial Blood Pressure-2.92 ± 2.298-1.15 ± 2.227
SecondaryChange From Baseline in Diastolic Arterial Blood Pressure

Change from baseline in diastolic arterial blood pressure (mmHg) was measured via right heart catheterization according to the local hospital procedures. The diastolic arterial blood pressure was assessed when the participant was in a stable hemodynamic rest state.

Time frame:
baseline and week 24
Reported as:
Least squares mean · mm Hg
Change From Baseline in Diastolic Arterial Blood Pressure
mm HgImatinibPlacebo
Change From Baseline in Diastolic Arterial Blood Pressure-3.81 ± 1.958-1.48 ± 1.909
SecondaryChange From Baseline in Heart Rate

Change from baseline in heart rate (bpm) was measured via right heart catheterization according to the local hospital procedures. The heart rate was assessed when the participant was in a stable hemodynamic rest state.

Time frame:
24 weeks
Reported as:
Least squares mean · bpm
Change From Baseline in Heart Rate
bpmImatinibPlacebo
Change From Baseline in Heart Rate0.38 ± 12.630.73 ± 2.255
SecondaryChange in Borg Dyspnea Score During 6-minute Walk Test

Change in Borg scale was measured at different time points at week 24. The Borg Scale consists of scale range of 0 to 10. Participants pointed to indicate their level of dyspnea before and at the end of exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). A reduction in this score indicates an improvement.

Time frame:
week 24
Reported as:
Mean · units on a scale
Change in Borg Dyspnea Score During 6-minute Walk Test
units on a scaleImatinibPlacebo
Resting (n= 86 imatinib; 89 placebo)-0.06 ± 1.097-0.12 ± 1.142
End of test (n= 92 imatinib; 91 placebo)-0.38 ± 2.009-0.24 ± 2.093
2 min after end (n= 82 imatinib; 81 placebo)-0.37 ± 1.409-0.18 ± 1.550
End of test - Resting (n= 81 imatinib; 81 placebo)-0.24 ± 1.193-0.29 ± 1.279
2 min after end - end of test (n= 82 ima; 81plb)-0.07 ± 1.533-0.03 ± 1.743
SecondaryCovariance of End of Study CAMPHOR Score

The CAMPHOR test consists of 65 items and 3 scales. Two scales measure Health Related Quality of Life. 1) Symptoms: consists of 25 items measuring loss or abnormality of psychological, physiological or anatomical structure or function; further sub-divided into 3 subscales (energy, breathlessness and mood), 2) Disability: consists of 15 items measuring any restriction or lack of ability to perform an activity. 3) Quality of Life (QOL): consists of 25 items defining how individuals perceived ability and capacity to satisfy their needs. The 25-item symptom and QOL scales score from 0-25 where a higher score indicates the presence of more symptoms and poor QOL, respectively. The 15-item functioning scale scores 0-30; a higher score indicates poor functioning.

Time frame:
Week 24
Reported as:
Least squares mean · units on a scale
Covariance of End of Study CAMPHOR Score
units on a scaleImatinibPlacebo
Symptoms score7.93 ± 1.3729.03 ± 1.431
Activity score8.99 ± 1.17710.55 ± 1.223
Quality of life score7.45 ± 1.0267.13 ± 1.066
SecondaryPlasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant

Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.

Time frame:
predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168
Reported as:
Mean · ng/mL
Plasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant
ng/mLImatinib 200 mgGCP74588
Day 1 - predose (n=77 imat; n=77 GCP)0 ± 00 ± 0
Day 1 - 0-3h post-dose (n=77 imat; n=77 GCP)471.9 ± 560.161.8 ± 77.6
Day 14 - predose (n=18 imat; n=18 GCP)579.6 ± 384.9178.8 ± 122.8
Day 14 - 0-3h post-dose (n=19 imat; n=19 GCP)1005.7 ± 665.6233.8 ± 170.9
Day 28 - predose (n=20 imat; n=20 GCP)658.8 ± 450.3228.6 ± 121.4
Day 28 - 0-3h post-dose (n=19 imat; n=19 GCP)1438.6 ± 924.4323.9 ± 150.6
Day 168 predose (n=24 imat; n=24 GCP)398.6 ± 415.5126.6 ± 83.3
Day 168- 0-3h post-dose (n=23 imat; n=23 GCP)710.8 ± 639.7166.1 ± 103.1
SecondaryPlasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant

Blood samples were taken from each subject participating in the study (placebo group and active treatment group) once predose and once between 0 hour to 3 hour post dose at day 1 (baseline), day 14, day 28 and day 168. The parent compound QTI571 and its active metabolite, GCP74588, were measured in plasma by validated liquid chromatography-mass spectrometry (HPLC-MS/MS) assay.

Time frame:
predose and between 0 hour to 3 hour post dose at day 1, day 14, day 28 and day 168
Reported as:
Mean · ng/mL
Plasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant
ng/mLImatinib 400 mgGCP74588
Day 1 - predose (n=12 imat; n=12 GCP)0 ± 00 ± 0
Day 1 - 0-3h post-dose (n=13 imat; n=13 GCP)843.2 ± 788.9109.9 ± 132.4
Day 14 - predose (n=62 imat; n=62 GCP)516.5 ± 405.2155.1 ± 101.1
Day 14 - 0-3h post-dose (n=62 imat; n=62 GCP)1172.8 ± 1088.9233.7 ± 165.6
Day 28 - predose (n=55 imat; n=55 GCP)829.8 ± 482.6248.2 ± 125.2
Day 28 - 0-3h post-dose (n=58 imat; n=58 GCP)1335.3 ± 817.9320.7 ± 154.8
Day 168 predose (n=36 imat; n=36 GCP)869.9 ± 407.8241.4 ± 91.9
Day 168- 0-3h post-dose (n=35 imat; n=35 GCP)1616.1 ± 787.6348.0 ± 119.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib—45/103 (43.7%)96/103 (93.2%)
Placebo—29/98 (29.6%)80/98 (81.6%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventImatinibPlacebo
AnaemiaBlood and lymphatic system disorders7/1031/98
Oedema peripheralGeneral disorders6/1030/98
DyspnoeaRespiratory, thoracic and mediastinal disorders6/1032/98
SyncopeNervous system disorders1/1035/98
PresyncopeNervous system disorders5/1030/98
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders4/1034/98
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders2/1034/98
DiarrhoeaGastrointestinal disorders3/1032/98
Device related infectionInfections and infestations3/1030/98
Right ventricular failureCardiac disorders2/1032/98
Most frequent other events
Showing 10 of 36
Most frequent other events
EventImatinibPlacebo
NauseaGastrointestinal disorders56/10323/98
Oedema peripheralGeneral disorders41/10320/98
DiarrhoeaGastrointestinal disorders33/10318/98
Periorbital oedemaEye disorders30/1037/98
VomitingGastrointestinal disorders30/10310/98
HeadacheNervous system disorders25/10322/98
NasopharyngitisInfections and infestations18/10319/98
CoughRespiratory, thoracic and mediastinal disorders11/10315/98
HypokalaemiaMetabolism and nutrition disorders14/1033/98
DyspnoeaRespiratory, thoracic and mediastinal disorders13/10311/98

Baseline characteristics

Age set includes all randomized participants (202). Gender set includes all treated participants (201). One participant was randomized to placebo but did not receive stuy drug.

Age, Continuous
Age, Continuous(years)Imatinib MesylatePlaceboTotal
Mean50.0 ± 15.3346.5 ± 13.6048.3 ± 14.59
Gender
Gender(participants)Imatinib MesylatePlaceboTotal
Female8379162
Male201939
08

Study locations

95 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35294, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85013, United States
  • Novartis Investigative Site
    Los Angeles, California 90024, United States
  • Novartis Investigative Site
    San Francisco, California 94143, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Clearwater, Florida 33756, United States
  • Novartis Investigative Site
    Miami Beach, Florida 33140, United States
  • Novartis Investigative Site
    Weston, Florida 33331, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30342, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21205, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02118, United States
  • Novartis Investigative Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68131, United States
  • Novartis Investigative Site
    Minneola, New York 11501-3893, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    New York, New York 10032, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45219, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Novartis Investigative Site
    Portland, Oregon 97210, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19140, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15212, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novartis Investigative Site
    Knoxville, Tennessee 37934, United States
  • Novartis Investigative Site
    Dallas, Texas 75390, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53215, United States
  • Novartis investigative site
    Innsbruck, Austria
  • Novartis Investigative Site
    Vienna, Austria
  • Novartis Investigative Site
    Bruxelles, Belgium
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Calgary, Canada
  • Novartis Investigative Site
    Edmonton, Canada
  • Novartis Investigative Site
    London, Canada
  • Novartis Investigative Site
    Montreal, Canada
  • Novartis Investigative Site
    Ottawa, Canada
  • Novartis investigative site
    Toronto, Canada
  • Novartis Investigative Site
    Vancouver, Canada
  • Novartis Investigative Site
    Clamart Cedex, France
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Dresden, Germany
  • Novartis Investigative Site
    Giessen, Germany
  • Novartis Investigative Site
    Greifswald, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Hannover, Germany
  • Novartis Investigative Site
    Heidelberg, Germany
  • Novartis Investigative Site
    Homburg, Germany
  • Novartis Investigative Site
    Koln, Germany
  • Novartis investigative site
    Lowenstein, Germany
  • Novartis Investigative Site
    Munchen, Germany
  • Novartis Investigative Site
    Regensberg, Germany
  • Novartis Investigative Site
    Wurzberg, Germany
  • Novartis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Pavia, Italy
  • Novartis Investigative Site
    Pisa, Italy
  • Novartis Investigative Site
    Roma, Italy
  • Novartis Investigative Site
    Bunkyo-ku, Japan
  • Novartis Investigative Site
    Hamamatsu, Japan
  • Novartis Investigative Site
    Mitaka, Japan
  • Novartis Investigative Site
    Okayama, Japan
  • Novartis Investigative Site
    Sendai, Japan
  • Novartis Investigative Site
    Suita, Japan
  • Novartis Investigative Site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, Netherlands
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigative Site
    Caceras, Spain
  • Novartis Investigative Site
    La Coruna, Spain
  • Novartis investigative site
    La Laguna, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canarias, Spain
  • Novartis Investigative Site
    Madrid, Spain
  • Novartis Investigative Site
    Malaga, Spain
  • Novartis Investigative Site
    Santa Cruz de Tenerife, Spain
  • Novartis Investigative Site
    Santander, Spain
  • Novartis Investigative Site
    Sevilla, Spain
  • Novartis investigative site
    Valencia, Spain
  • Novartis Investigative Site
    Valladolid, Spain
  • Novartis Investigative Site
    Lund, Sweden
  • Novartis Investigative Site
    Stockholm, Sweden
  • Novartis Investigative Site
    Umea, Sweden
  • Novartis Investigative Site
    Uppsala, Sweden
  • University Hospital Basel
    Basel, Switzerland
  • Novartis Investigative Site
    Bern, Switzerland
  • Novartis Investigative Site
    Lausanne, Switzerland
  • Novartis Investigative Site
    St. Gallen, Switzerland
  • Novartis Investigative Site
    Cambridge, United Kingdom
  • Novartis Investigative Site
    Clydebank, United Kingdom
  • Novartis Investigative Site
    London, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, United Kingdom
  • Novartis Investigative Site
    Sheffield, United Kingdom
09

References and documents

Publications

  • Querejeta Roca G, Campbell P, Claggett B, Solomon SD, Shah AM. Right Atrial Function in Pulmonary Arterial Hypertension. Circ Cardiovasc Imaging. 2015 Nov;8(11):e003521; discussion e003521. doi: 10.1161/CIRCIMAGING.115.003521. PubMed 26514759 ↗
  • Querejeta Roca G, Campbell P, Claggett B, Vazir A, Quinn D, Solomon SD, Shah AM. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. Eur J Heart Fail. 2015 Jan;17(1):63-73. doi: 10.1002/ejhf.177. Epub 2014 Nov 4. PubMed 25367310 ↗
  • Shah AM, Campbell P, Rocha GQ, Peacock A, Barst RJ, Quinn D, Solomon SD; IMPRES Investigators. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J. 2015 Mar 7;36(10):623-32. doi: 10.1093/eurheartj/ehu035. Epub 2014 Feb 23. PubMed 24566799 ↗
  • Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12. PubMed 23403476 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years 2 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2009
First posted
May 15, 2009
Start
Sep 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Apr 27, 2012
Results first posted
Jul 16, 2013
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00902174
Responsible party
Sponsor
First posted
May 15, 2009
Start date
Sep 2009
Primary completion
May 2011
Completion
May 2011
Results posted
Jul 16, 2013
Last update
Feb 17, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion